RxDoctor Payments Data

Christina Ancheta

Family · Newport News, VANPI 1497395446

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 51 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$323
  • Novartis$203
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$179
  • Philips North America LLC$169
  • Merck$96
  • Johnson & Johnson$89
  • plus $272 from 8 others

What the payments were for

  • Food & beverage$1,332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,332 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$35,650
Medicare patients
373
Services billed
668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$237,610
XareltoRivaroxaban70$72,138
EntrestoSacubitril/Valsartan74$64,513
Repatha SureclickEvolocumab32$34,297
FarxigaDapagliflozin Propanediol18$17,024
MultaqDronedarone Hcl14$13,331
JardianceEmpagliflozin11$11,739
BrilintaTicagrelor14$10,152
Metoprolol Succinate241$2,742
Ranolazine ErRanolazine33$2,300
Amiodarone Hcl39$2,010
Atorvastatin Calcium142$1,622
Isosorbide Mononitrate ErIsosorbide Mononitrate103$1,555
Losartan Potassium117$1,203
Prasugrel Hcl11$1,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$237,610220 claims
Johnson & JohnsonXarelto$89$72,13870 claims
NovartisEntresto$203$64,51374 claims
AstraZenecaFarxiga, Brilinta$16$27,17732 claims
Sanofi-aventis U.S. LLCMultaq$21$13,33114 claims
Boehringer IngelheimJardiance$69$11,73911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →